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Abstract
Importance—Despite antirestenotic efficacy of coronary drug-eluting stents (DES) compared 
with bare metal stents (BMS), the relative risk of stent thrombosis and adverse cardiovascular 
events is unclear. Although dual antiplatelet therapy (DAPT) beyond one year provides ischemic 
event protection following DES, ischemic event risk is perceived to be less following BMS and 
the appropriate duration of DAPT following BMS is unknown.
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Objective—To compare: (1) rates of stent thrombosis and major adverse cardiac and 
cerebrovascular events (MACCE; composite of death, myocardial infarction, or stroke) after 30 
vs. 12 months of thienopyridine in patients treated with BMS taking aspirin; and (2) treatment 
duration effect within the combined cohorts of randomized DES or BMS-treated patients as 
prespecified, secondary analyses of the Dual Antiplatelet Therapy Study.
Design, Setting, Participants—International, multicenter, randomized, double-blinded, 
placebo-controlled trial, comparing extended (30 months) thienopyridine versus placebo in 
aspirin-treated patients who completed 12 months of DAPT without bleeding or ischemic events 
post-stenting. Study initiation August 2009 with last follow-up visit May 2014.
Exposure/Intervention—Continued thienopyridine or placebo at months 12-30 after stenting, 
in 11648 randomized patients treated with aspirin, of whom 1687 received BMS and 9961 DES.
Main Outcome and Measures—Stent thrombosis, MACCE, moderate/severe bleeding.
Results—Among 1687 BMS-treated patients randomized to continued thienopyridine vs. 
placebo, rates of stent thrombosis were 0.5% vs. 1.11%, (N=4 vs. 9, hazard ratio 0.49, 95% CI 
0.15-1.64, P=0.24), MACCE 4.04% vs. 4.69%, (N=33 vs. 38, hazard ratio 0.92, 95% CI 0.57-1.47, 
P=0.72) and moderate/severe bleeding 2.03% vs. 0.90% (N=16 vs. 7, P=0.07), respectively. 
Among all 11,648 randomized patients (both BMS- and DES-treated), stent thrombosis rates were 
0.41% vs. 1.32%, (N=23 vs. 74, hazard ratio 0.31, 95% CI 0.19-0.50, P<0.001), MACCE 4.29% 
vs. 5.74% (N=244 vs. 323, hazard ratio 0.73, 95% CI 0.62-0.87, P<0.001), and moderate/severe 
bleeding 2.45% vs. 1.47% (N=135 vs. 80, P<0.001).
Conclusions and Relevance—Among patients undergoing coronary stenting with BMS and 
who tolerated 12 months of thienopyridine, continuing thienopyridine for an additional 18 months 
compared with placebo did not result in statistically significant differences in rates of stent 
thrombosis, MACCE, or moderate/severe bleeding. However, the BMS subset may have been 
underpowered to identify such differences and further trials are suggested. (DAPT 
ClinicalTrials.gov number NCT00977938).
Introduction
While current clinical practice guidelines recommend a minimum of only 1 month of dual 
antiplatelet therapy (DAPT) after bare metal stent (BMS) placement following elective 
percutaneous coronary intervention (PCI; compared with 6-12 months for drug-eluting 
stents [DES]),1,2 patients with acute coronary syndromes (ACS) benefit from 12 months of 
therapy whether or not PCI with stenting is performed.3 Although randomized trial results 
(the Dual Antiplatelet Therapy Study)4 showed a reduction in stent thrombosis and non-stent 
related myocardial infarction (MI) with thienopyridine therapy beyond 12 months following 
DES (among patients tolerating DAPT to 12 months), few trials have assessed optimal 
duration of DAPT following BMS.5 Because BMS remain a commonly used alternative 
treatment strategy to DES, particularly for patients who present with ACS or in whom 
DAPT has perceived increased bleeding risk,6,7 we aimed to compare (1) rates of stent 
thrombosis or major adverse cardiovascular and cerebrovascular events (MACCE) in 
randomized BMS-treated patients and (2) treatment duration effect among all randomized 
patients in the Dual Antiplatelet Therapy Study.
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Methods
Study Objectives and Hypotheses
We compared the randomized treatment effect of continued thienopyridine vs. placebo 
beyond 12 months with regard to stent thrombosis, MACCE, and bleeding after 
randomization until the completion of study drug treatment at 30 months among BMS-
treated patients as well as the combined BMS- and DES-treated cohort. As a post hoc 
analysis, we assessed the consistency of treatment duration effect between patients treated 
with BMS or DES.
Study Design
The DAPT Study design has previously been described.8 This double-blind, international, 
randomized clinical trial compared the risks and benefits of continued thienopyridine 
(clopidogrel or prasugrel) versus placebo, when given in addition to aspirin for the 
prevention of stent thrombosis or MACCE following coronary stenting with either DES or 
BMS in patients who tolerated DAPT to 12 months (ClinicalTrials.gov # NCT00977938). 
The results comparing randomized treatments in the DES-treated cohort have been reported 
separately.4
All institutions received approval from their Institutional Review Boards and each patient 
provided written informed consent for study participation.
Study Population and Procedures
In brief, patients who were candidates for DAPT and who received treatment with either 
DES or BMS were recruited. Stent treatment was performed according to site standards of 
care using only Food and Drug Administration-approved DES and BMS devices. DES types 
included Cypher sirolimus-eluting stent (Cordis, Warren, NJ), Endeavor zotarolimus-eluting 
stent (Medtronic, Santa Rosa, CA), TAXUS paclitaxel-eluting stent (Boston Scientific, 
Marlborough, MA), and Xience/Promus everolimus-eluting stents (Abbott Vascular, Santa 
Clara, CA or Boston Scientific, Marlborough, MA). All patients >18 years of age who met 
all enrollment inclusion and none of the exclusion criteria (Appendix Table 2), and signed 
the consent and were enrolled into the trial within 3 days of the index procedure and all 
received open-label aspirin plus thienopyridine for the first 12 months. As required by 
regulatory authorities, race and ethnicity data were collected via patient self-report. Race 
categories for this study were pre-specified as America Indian or Alaska Native, Asian, 
Black or African American, Native Hawaiian or Other Pacific Islander, White and Other, 
specify. Ethnicity was collected as Hispanic or Latino and Not Hispanic or Latino. At 12 
months, patients who were alive and free from MI, stroke, repeat coronary revascularization, 
stent thrombosis, and moderate or severe bleeding and who demonstrated compliance with 
thienopyridine treatment were then eligible for randomization (Figure 1) to continued 
thienopyridine or placebo, and all continued aspirin. A computer-generated randomization 
schedule stratified patients according to the type of stent they had received (drug eluting vs. 
bare metal), hospital site, thienopyridine type, and presence or absence of at least one 
prespecified clinical- or lesion-related risk factor for stent thrombosis (see Appendix Table 
1).
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Post-randomization study procedures and follow-up were the same for BMS- and DES-
treated patients.
Study Endpoints
The co-primary effectiveness end points were cumulative incidence of definite/probable 
stent thrombosis according to the Academic Research Consortium classification9 and 
incidence of MACCE at 12-30 months. For randomized comparison of DAPT duration 
among BMS-treated patients, the primary safety endpoint was moderate or severe bleeding 
(Global Utilization of Streptokinase and TPA for Occluded Arteries [GUSTO] 
classification)10 at 12-30 months. Finally, clinically actionable non-coronary artery bypass 
graft related bleeding was also evaluated according to the Bleeding Academic Research 
Consortium definitions (BARC 2, 3 or 5 classes).11 These events were adjudicated by an 
independent Clinical Events Committee blinded to treatment assignment and administered 
by HCRI. An unblinded independent central data monitoring committee oversaw the safety 
of all patients.
Statistical Analysis
Among patients treated with BMS and randomized to continued thienopyridine vs. placebo, 
the cumulative incidence of stent thrombosis and of MACCE are presented according to 
intention-to-treat. Treatments were compared using a log-rank test stratified by geographic 
region (North America, Europe, and Australia/New Zealand), thienopyridine type, and 
presence/absence of stent thrombosis risk factors (listed in Table 1).8 For each endpoint, the 
stratified hazard ratio (HR) and its 2-sided 95% CI comparing continued thienopyridine vs. 
placebo are presented. Patients not experiencing the co-primary endpoints 12-30 months 
post-index procedure were censored at the time of last known contact or 30 months, 
whichever was earlier.
The analysis of the BMS cohort comparing randomized treatment arms was a prespecified 
secondary analysis of the DAPT Study that was not powered to compare treatment arms 
within this cohort (the powered DES-treated cohort has been previously presented4) but was 
performed to assess consistency of the randomized treatment effect in BMS- vs. DES-treated 
patients from the Dual Antiplatelet Therapy Study. Stent-type-by-randomized treatment 
interaction was assessed using Cox proportional hazards regression as a post hoc analysis, 
and the stratified HR, 95% CI, and P values for interaction are presented. All other analyses 
presented were prespecified.
All statistical analyses were conducted at HCRI with SAS software, version 9.2. (SAS 
Institute Inc., Cary, NC). All p-values are two-sided and considered significant at the 0.05 
level.
Results
Study Population
Enrollment in the Dual Antiplatelet Therapy Study was conducted between August 
2009 and July 2011, with the last follow-up visit conducted in May 2014. Of 2816 enrolled 
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BMS-treated patients, 583 (20.7%) were not eligible for randomization after 12 months of 
follow-up, 546 (19.4%) were eligible but not randomized, and 1687 (59.9%) were 
randomized (Figure 1). Of 25682 total enrolled patients, 5844 (22.8%) were not eligible for 
randomization after 12 months of follow-up, 8190 (31.9%) were eligible but not 
randomized, and 11648 (45.4%) were randomized, with median follow up of 990 days (25% 
Q1: 981 days; 75% Q2: 990 days) (Appendix Figure 1). The most common reason for non-
randomization was withdrawal of patient consent.
Baseline characteristics of BMS-treated randomized patients were similar between the 
groups (Table 1). While the same inclusion and exclusion criteria were applied to all 
enrolled patients, DES- and BMS-treated patients differed according to clinical and 
procedural characteristics (Appendix Table 1). DES-treated patients were more likely to 
have a history of diabetes mellitus (30.6% vs. 21.2%, P<0.001), hypertension, previous PCI, 
and to have longer lesions, with smaller reference vessel diameter, while BMS-treated 
patients were more likely to present with ST-elevation MI (STEMI, 37.6% vs. 10.5%, 
P<0.001), or non-STEMI (20.9% vs. 15.5%, P<0.001), and were more likely to have 
thrombus noted in the treated lesion. The baseline characteristics of the randomized, DES-
treated patients have been previously published.4 Baseline characteristics of all randomized 
patients were similar between the randomly assigned treatment groups (Appendix Table 1). 
Predefined risk factors for stent thrombosis were present in 54% of patients in each 
randomly assigned treatment group.
Effect of Continued Thienopyridine Therapy Among BMS–Treated Patients
Within randomized BMS-treated patients, the cumulative incidence of stent thrombosis and 
MACCE were 0.5% vs. 1.1% (HR 0.49, 95% CI 0.15-1.64, log-rank P=0.24) and 4.0% vs. 
4.7% (HR 0.92, 95% CI 0.57-1.47, log-rank P=0.72), respectively, for continued 
thienopyridine vs. placebo at 12-30 months after the index procedure (Table 2). GUSTO 
severe/moderate bleeding events occurred in 2.03% vs. 0.90% among BMS-treated patients 
randomized to continued thienopyridine vs. placebo (P=0.07); and BARC 2, 3, or 5 bleeding 
events occurred in 4.56% vs. 1.80% respectively (P=0.002). Severe bleeding was 
uncommon and fatal bleeding events (BARC 5) were rare and not different between 
treatment groups (Table 2).
The results comparing continued thienopyridine vs. placebo in the DES-treated cohort have 
been reported previously and demonstrated significant reductions in study co-primary 
endpoints of stent thrombosis (0.4% vs. 1.4%, respectively, HR 0.29, 95% CI 0.17-0.48) and 
MACCE (2.0% vs. 1.5%, respectively, HR 0.71, 95% CI 0.59-0.85) (driven by a reduction 
in both stent and non-stent related MI, Table 3). An increase in moderate/severe bleeding 
events was observed (2.5% vs. 1.6%, respectively, P=0.001), and a difference in all-cause 
mortality rate that was not statistically significant was seen 2.0% vs. 1.5% (p=0.052), yet 
mortality was infrequently related to bleeding (0.1% vs. 0.1% fatal bleeding, P=0.38, and 
0.22% vs. 0.06% bleeding-related mortality, p=0.57).1
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Consistency of Effects of Continued Thienopyridine Across BMS- and DES-Treated 
Patients
The post hoc analysis of the effect of continued thienopyridine found non-significant 
interactions between randomized BMS- and DES-treated patients for both stent thrombosis 
(interaction P=0.42) and MACCE (interaction P=0.32, Table 3).
Among all randomized patients, the co-primary effectiveness endpoints of stent thrombosis 
(0.41% vs. 1.32%; HR 0.31, 95% CI 0.19-0.50; P<0.001) and MACCE (4.29% vs. 5.74%; 
HR 0.73, 95% CI 0.62-0.87; P<0.001) were reduced by continued thienopyridine versus 
placebo, respectively (Table 4). The reduction in stent thrombosis was largely explained by 
a reduction in definite stent thrombosis and the reduction in MACCE was largely explained 
by a 48% relative reduction (1.83% absolute) in MI. Significant reductions in MI related to 
stent thrombosis (0.38% vs. 1.28%, HR 0.29, 95% CI 0.18-0.48; P<0.001) as well as MI not 
related to stent thrombosis (1.84% vs. 2.75%, HR 0.65, 95% CI 0.50-0.84; P<0.001) were 
observed. In contrast, there is an increased incidence of severe/moderate bleeding events 
(2.45% vs. 1.47%, risk difference 0.98, 95% CI 0.46-1.50; P<0.001) largely explained by 
the relative increase in moderate bleeding (1.65% vs. 0.96%, risk difference 0.70, 95% CI 
0.27-1.12; P=0.001). Similarly, although BARC Types 2, 3, or 5 bleeding events were 
significantly increased in the continued thienopyridine treatment group (5.44% vs. 2.78%, 
HR 2.65, 95% CI 1.91-3.40; P<0.001), fatal (Type 5) BARC bleeding events were rare and 
not different between groups (0.13% vs. 0.09%, HR 0.04, 95% CI -0.09 to 0.16; p=0.58; 
Table 4).
Discussion
Among patients undergoing coronary stenting with BMS and who tolerated 12 months of 
thienopyridine, continuing thienopyridine for an additional 18 months compared to placebo 
did not result in statistically significant differences in rates of stent thrombosis, MACCE, or 
moderate/severe bleeding. However, limitations in sample size and power make definitive 
conclusions regarding DAPT treatment duration effects difficult. While fewer BMS-treated 
patients were enrolled and randomized because of the prevailing use of DES in clinical 
practice, among patients eligible for continued DAPT, in a post hoc analysis we found non-
significant interactions for the effect of continued thienopyridine therapy on stent 
thrombosis among BMS- and DES-treated patients who were randomized in the Dual 
Antiplatelet Therapy Study.4 However, as this comparison of treatment interaction was not 
adequately powered for definitive interpretations, true differences in treatment effect size 
may not have been detected and the observation that continued thienopyridine therapy 
beyond one year (in patients who tolerated DAPT for one year without major bleeding) may 
prevent ischemic events independent of stent type (DES or BMS) should be considered 
hypothesis-generating.
Indeed, BMS-treated patients accrue target lesion (stent) related events in ≥2% per year12 
and non-target lesion/vessel events in ≥5% per year following stent deployment.13,14 Late 
atherothrombotic events following BMS may be due to lack of healing/uncovered stent 
struts, neoatherosclerosis,15 restenosis,16 or disease progression outside the stent, in other 
regions or vessels. The largest portion of MI prevented by extended duration thienopyridine 
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therapy in this study did not involve the stented coronary segments for either DES or BMS. 
While bleeding events were similarly increased with continued thienopyridine therapy 
beyond one year in both BMS and DES treated patients, these events were infrequently 
severe and rarely fatal (BARC 5 classification).11 The numeric increase in mortality 
associated with continued thienopyridine therapy (2.0 vs. 1.5%, p=0.052) that was observed 
in the DES-treated cohort, was not evident among BMS-treated randomized patients (1.0% 
vs. 1.2%, P=0.83).
The lack of apparent treatment interaction between DES and BMS supports the combined 
analysis of treatment effects of continued duration of therapy independent of stent type. 
Among the combined BMS and DES cohort, the reductions in stent thrombosis and MACCE 
were 69% and 27%, respectively in patients continuing thienopyridine therapy together with 
aspirin. 50% of the MIs prevented by continued DAPT were not stent thrombosis related. 
These ischemic event benefits were balanced by a 67% relative increase in moderate 
bleeding
Limitations
The major limitation of the BMS randomized comparison of DAPT duration is sample size 
and lack of power which limits the interpretability of the findings. However, an adequately 
powered randomized BMS cohort would require approximately 8,000 additional patients, 
which was practically not feasible under financial and logistic constraints of the study. An 
adequate number of BMS-treated patients were enrolled to allow a powered comparison of 
stent thrombosis and MACCE rates with patients treated with DES,17 the results of which 
have been presented separately.18 In this context, the design of the BMS randomized 
comparison was to evaluate for consistency or heterogeneity compared with the DES 
treatment effect in an exploratory fashion, rather than to be powered for a separate, 
independent analysis. Nonetheless, the BMS cohort sample size exceeds that of prior 
randomized BMS cohorts evaluating duration of antiplatelet therapy5 and is similar in size 
to many prior randomized trials of DAPT duration in DES.5,19-22 While similar inclusion 
criteria were required of BMS- and DES-treated patients, there were systematic differences 
between BMS- and DES-treated patients with a higher frequency of MI presentation prior to 
the index PCI procedure for BMS and a higher prevalence of restenosis risk factors for DES-
treated patients. Nevertheless, each cohort was balanced across randomized treatment arms 
as expected according to the stratified randomization.
Conclusions
Among patients undergoing coronary stenting with BMS and who tolerate 12 months of 
thienopyridine and aspirin therapy without major bleeding, continuing thienopyridine 
therapy in addition to aspirin beyond 12 months, did not result in statistically significant 
differences in rates of stent thrombosis, MACCE or moderate/severe bleeding. However, the 
BMS subset may have been underpowered to determine such differences.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Enrollment, Randomization, and Follow-up Among Randomized Bare Metal Stent-Treated 
Patients.
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Table 1
Baseline Characteristics of Randomized Bare Metal Stent-Treated Patients.*
Characteristics Continued Thienopyridine
N=842
Placebo
N=845
% (N) reported for non-continuous variable
Patients
Age (years), mean ±SD 58.9 ±10.5 59.2 ±11.1
Female 25.5% (215) 21.8% (184)
Race- non-White** 7.5% (62) 7.3% (61)
Weight (kg), mean ±SD 88.0 ±18.4 88.5 ±18.8
BMI(Kg/m2), mean ±SD 29.5 ±5.2 29.6 ±5.6
Diabetes mellitus 21.7% (181) 20.7% (173)
Hypertension 64.0% (534) 64.6% (543)
Cigarette smoker 43.3% (360) 43.3% (350)
Stroke/TIA 5.1% (43) 4.0% (34)
Congestive heart failure 4.2% (35) 3.3% (28)
Peripheral arterial disease 4.2% (35) 5.5% (46)
Prior PCI 17.9% (150) 20.3% (171)
Prior CABG 6.0% (50) 5.9% (50)
Prior MI 19.4% (160) 21.5% (178)
Indication for PCI 58.8% 58.3%
 ACS 58.8% (495) 58.3% (493)
  STEMI 36.9% (311) 38.3% (324)
  NSTEMI 21.9% (184) 20.0% (169)
 Unstable Angina*** 9.1% (77) 9.6% (81)
 Stable Angina 23.6% (199) 23.4% (198)
 Other 8.4% (71) 8.6% (73)
Any risk factor for stent thrombosis 69.2% (568) 69.0% (569)
 Any Clinical 64.0% (525) 63.2% (521)
  Enzyme positive ACS (STEMI or NSTEMI) 58.8% (495) 58.3% (493)
  Renal insufficiency/failure 3.4% (28) 2.4% (20)
  LVEF < 30% 4.0% (32) 3.6% (29)
 Any Lesion-Related 38.7% (325) 37.5% (316)
  > 2 vessels stented 0.0% (0) 0.1% (1)
  > 2 lesions per vessel 1.1% (9) 1.0% (8)
  Lesion length ≥ 30 mm 6.5% (55) 6.6% (56)
  Bifurcation lesion sidebranch ≥ 2.5 mm 4.5% (38) 4.0% (34)
  In-stent restenosis of a DES 0.4% (3) 0.7% (6)
  Vein bypass graft stented 2.6% (22) 2.4% (20)
  Unprotected left main stented 0.0% (0) 0.1% (1)
  Thrombus-containing lesion 28.9% (243) 25.9% (219)
  Prior Brachytherapy 0.1% (1) 0.1% (1)
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Characteristics Continued Thienopyridine
N=842
Placebo
N=845
% (N) reported for non-continuous variable
Region
 North America 60.5% (509) 61.4% (519)
 Europe 36.1% (304) 35.5% (300)
 Australia or New Zealand 3.4% (29) 3.1% (26)
Thienopyridine drug at randomization
 Clopidogrel 86.7% (730) 86.6% (732)
 Prasugrel 13.3% (112) 13.4% (113)
Number of treated lesions, mean ±SD 1.2 ±0.4 1.12 ±0.4
Number of treated vessels, mean ±SD 1.0 ±0.2 1.1 ±0.2
Number of stents, mean ±SD 1.3 ±0.6 1.3 ±0.6
Minimum stent diameter (per subject)
 <3 23.9% (201) 24.4% (206)
 ≥3 76.1% (641) 75.6% (639)
Total stent length (mm), mean ±SD 24.0 ±13.0 23.9 ±13.1
Lesions†
Treated Vessel
  Left main 0.0% (0) 0.1% (1)
  LAD 31.6% (308) 30.9% (306)
  Right 44.8% (437) 45.6% (452)
  Circumflex 21.1% (206) 20.9% (207)
 Venous graft 2.5% (24) 2.5% (25)
 Arterial graft 0.0% (0) 0.0% (0)
Modified ACC/AHA lesion class B2 or C 47.6% (440) 47.8% (450)
Abbreviations: ACC, American College of Cardiology; ACS, acute coronary syndrome; AHA, American Heart Association; BMI, body mass 
index; CABG, coronary artery bypass graft; DES, drug-eluting stent; LAD, left anterior descending; LVEF, left ventricular ejection fraction; MI, 
myocardial infarction; NSTEMI, non-ST elevation MI; PCI, percutaneous coronary intervention; STEMI, ST-elevation MI; TIA, transient ischemic 
attack.
*
For all variables, 0-4% of subjects had missing values.
**
Race was self-reported.
***
This category included unstable angina without reported elevation of cardiac enzymes.
†A total of 975 lesions were treated in the continued thienopyridine group and 991 in the placebo group.
‡
The definitions of class B2 and class C lesions according to the modified American College of Cardiology (ACC)–American Heart Association 
(AHA) criteria.23
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Table 2
Ischemic and Bleeding Outcomes In Randomized Bare Metal Stent-Treated Patients
Patients were randomized to continued thienopyridine or placebo plus aspirin 12 months after receiving a bare 
metal stent. The effectiveness endpoints, stent thrombosis and MACCE, are shown over the primary analysis 
period, e.g. 12-30 months after enrollment. For the safety endpoint of GUSTO severe or moderate bleeding, 
patients whose last contact date was ≥ 510 days post randomization or who experienced any adjudicated 
bleeding outcome at or before 540 days were included.
Continued Thienopyridine
N=8421
Placebo
N=8451
Hazard Ratio
(95% CI)
Log-rank P-Value
Ischemic Outcomes No. of patients (%)
Stent thrombosis* 4 (0.50) 9 (1.11) 0.49 (0.15, 1.64) 0.24
 Definite 4 (0.50) 9 (1.11) 0.49 (0.15, 1.64) 0.24
 Probable 0 (0.00) 0 (0.00) N/A .
MACCE (death, MI, stroke) 33 (4.04) 38 (4.69) 0.92 (0.57, 1.47) 0.72
 Death, all cause 8 (0.99) 10 (1.24) 0.90 (0.35, 2.33) 0.83
 MI 22 (2.70) 25 (3.10) 0.91 (0.51, 1.62) 0.74
  Stent thrombosis-related 4 (0.50) 9 (1.11) 0.49 (0.15, 1.64) 0.24
  Non stent thrombosis-related 18 (2.21) 16 (1.99) 1.12 (0.57, 2.20) 0.74
 Stroke (total) 6 (0.73) 5 (0.62) 1.22 (0.37, 4.01) 0.74
  Ischemic 4 (0.49) 5 (0.62) 0.82 (0.22, 3.05) 0.77
  Hemorrhagic 1 (0.12) 0 (0.00) N/A 0.32
  Type Uncertain 1 (0.12) 0 (0.00) N/A 0.32
Bleeding Complications** Continued Thienopyridine
N=790
Placebo
N=776
Risk Difference 2-Sided P Value for Difference
No. of patients (%) Percentage points (95% CI)
GUSTO Severe/Moderate 16 (2.03) 7 (0.90) 1.12% (-0.06%,2.31%) 0.07
 GUSTO Severe 6 (0.76) 3 (0.39) 0.37% (-0.37%,1.12%) 0.33
 GUSTO Moderate 10 (1.27) 4 (0.52) 0.75%(-0.18%,1.68%) 0.12
BARC Types 2, 3, or 5 36 (4.56) 14 (1.80) 2.75% (1.02%,4.48%) 0.002
 BARC Type 2 22 (2.78) 7 (0.90) 1.88% (0.56%,3.21%) 0.01
 BARC Type 3 16 (2.03) 6 (0.77) 1.25% (0.09%,2.41%) 0.04
 BARC Type 5 0 (0.00) 1 (0.13) -0.13% (-0.38%,0.12%) 0.31
Abbreviations: ARC, Academic Research Consortium; BARC, Bleeding Academic Research Consortium; GUSTO, Global Utilization of 
Streptokinase and TPA for Occluded Arteries; MACCE, major adverse cardiovascular and cerebrovascular events; MI, myocardial infarction.
Please see Supplementary Appendix: Table 3 for GUSTO and BARC definitions.
*
Definite and probable stent thrombosis were determined according to the criteria of the Academic Research Consortium.
**
The primary safety end point was moderate or severe bleeding as assessed according to GUSTO criteria. Only patients who could be evaluated 
were included in this analysis (i.e., patients whose last contact date was ≥510 days after randomization or who had any adjudicated bleeding event 
at or before 540 days). Patients could have had more than one bleeding episode. The secondary analysis of bleeding is assessed according to the 
criteria of the BARC criteria.
1
Percentages are Kaplan-Meier estimates.
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Table 3
Treatment Interaction by Stent Type on Outcomes
Analyses of treatment interaction by stent type, shown with Kaplan-Meier event rates, hazard ratios and 95% 
confidence intervals (CI) for efficacy and safety outcomes at 12-30 months among all randomized patients 
(9961 drug-eluting stent-treated and 1687 bare metal stent-treated).
Continued Thienopyridine
N (%)
Placebo
N (%)
Hazard Ratio
(95% CI) P Value for Interaction
No. of patients (%)
Definite or Probable Stent Thrombosis* 0.42
 DES 19 (0.4) 65 (1.4) 0.29 (0.17,0.48)
 BMS 4 (0.5) 9 (1.1) 0.49 (0.15,1.64)
MACCE 0.32
 DES 211 (4.3) 285 (5.9) 0.71 (0.59,0.85)
 BMS 33 (4.0) 38 (4.7) 0.92 (0.57,1.47)
Death 0.41
 DES 98 (2.0) 74 (1.5) 1.36 (1.00,1.85)
 BMS 8 (1.0) 10 (1.2) 0.90 (0.35,2.33)
GUSTO Severe/Moderate Bleeding 0.30
 DES 119 (2.5) 73 (1.5) 1.60 (1.19,2.17)
 BMS 16 (1.9) 7 (0.9) 2.74 (1.05,7.00)
Myocardial Infarction 0.04
 DES 99 (2.1) 198 (4.1) 0.47 (0.37,0.61)
 BMS 22 (2.7) 25 (3.1) 0.91 (0.51,1.62)
Abbreviations: BMS, bare metal stents; DES, drug-eluting stents; GUSTO, Global Utilization of Streptokinase and TPA for Occluded Arteries; 
MACCE, major adverse cardiovascular and cerebrovascular events.
*
Definite and probable stent thrombosis were determined according to the criteria of the Academic Research Consortium.
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Table 4
Ischemic and Bleeding Outcomes in All (Bare Metal and Drug-eluting Stent-Treated) Randomized Patients 
Comparing Continued Thienopyridine vs Placebo.
Outcome
Continued Thienopyridine
N=58621
Placebo
N=57861
Hazard Ratio
(95% CI) Log-rank P-Value
No. of patients (%)
Stent thrombosis* 23 (0.41) 74 (1.32) 0.31 (0.19, 0.50) <.001
 Definite 19 (0.34) 67 (1.20) 0.28 (0.17, 0.47) <.001
 Probable 5 (0.09) 7 (0.12) 0.71 (0.23, 2.24) 0.56
MACCE (Death, MI, Stroke) 244 (4.29) 323 (5.74) 0.73 (0.62, 0.87) <.001
 Death, all cause 106 (1.87) 84 (1.50) 1.31 (0.97, 1.75) 0.07
 MI 121 (2.15) 223 (3.98) 0.52 (0.42, 0.65) <.001
  Stent thrombosis-related 21 (0.38) 72 (1.28) 0.29 (0.18, 0.48) <.001
  Non stent thrombosis-related 104 (1.84) 154 (2.75) 0.65 (0.50, 0.84) <.001
 Stroke (total) 43 (0.76) 48 (0.86) 0.84 (0.55, 1.28) 0.42
  Ischemic 28 (0.50) 39 (0.70) 0.70 (0.43, 1.15) 0.16
  Hemorrhagic 14 (0.25) 9 (0.16) 1.31 (0.55, 3.12) 0.53
  Type uncertain 1 (0.02) 1 (0.02) 1.01 (0.06, 16.09) 1.00
Bleeding Complications**
Continued Thienopyridine
N=5500
Placebo
N=5425 Difference Two-sided P Value for Difference
No. of patients (%) Percentage points (95% CI)
GUSTO Severe/Moderate 135 (2.45) 80 (1.47) 0.98 (0.46, 1.50) <.001
 GUSTO Severe 44 (0.80) 29 (0.53) 0.27 (-0.04, 0.57) 0.09
 GUSTO Moderate 91 (1.65) 52 (0.96) 0.70 (0.27, 1.12) 0.001
BARC Types 2, 3, or 5 299 (5.44) 151 (2.78) 2.65 (1.91, 3.40) <.001
 BARC Type 2 167 (3.04) 79 (1.46) 1.58 (1.03, 2.13) <.001
 BARC Type 3 138 (2.51) 74 (1.36) 1.15 (0.63, 1.66) <.001
 BARC Type 5 7 (0.13) 5 (0.09) 0.04 (-0.09, 0.16) 0.58
Abbreviations: BARC, Bleeding Academic Research Consortium; GUSTO, Global Utilization of Streptokinase and TPA for Occluded Arteries, 
MACCE, major adverse cardiovascular and cerebrovascular events; MI, myocardial infarction.
*
Definite and probable stent thrombosis were determined according to the criteria of the Academic Research Consortium.
1
Percentages are Kaplan-Meier estimates.
Results for MACCE and stent thrombosis are for all randomized patients; patients not experiencing the endpoint are censored at 30 months or at 
last known follow-up, whichever is earlier.
**Only patients who could be evaluated were included in this analysis (i.e., patients whose last contact date was ≥510 days after randomization or 
who had any adjudicated bleeding event at or before 540 days). Patients could have had more than one bleeding episode.
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